January 25th, 2016, Vancouver, B.C. – Veritas Pharma Inc. (“VRT” or the “Company”) (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP) is pleased to announce that Dr. Domenico Spina has been appointed as a director of the Company.

Dr. Spina obtained his PhD from the University of Western Australia in 1988 and was awarded a C.G. Martin Fellowship from the National Health and Research Council of Australia to undertake postdoctoral studies at King’s College London (1988-1991), returning to Australia to continue his fellowship. He returned to the United Kingdom in 1994 as a Lecturer in Respiratory Pharmacology in the School of Medicine, Kings College London, and is now Reader in Pharmacology in the Faculty of Life Sciences and Medicine. He is currently head of Pharmacology and Therapeutics Research within the Institute of Pharmaceutical Science. Dr. Spina is a member of the British Pharmacological Society, American Thoracic Society and the European Respiratory Society. His research interest includes inflammation of the airways with particular emphasis on understanding the pharmacology of drugs used to treat cough, asthma, chronic obstructive disease and lung injury with a view to developing novel therapies for these conditions.

Dr. Spina commented that “I have been involved in investigating the role of phytocannabinoids as potential cannabis based treatments for respiratory disease in collaboration with GW Pharma; and after reviewing the team Dr. Lui Franciosi has assembled with Cannevert Therapeutics Ltd., I am more excited to be invited to be part of such a strong, well known, diverse team.”

Further, Dr. Spina states that “I am pleased to have joined the Board of Directors of Veritas Pharma Inc and look forward to participating in the development of exciting new cannabis based treatments for the benefit of patients.”

CEO, Lui Franciosi commented, “Having Dr. Spina on board, adds to the team. His vast knowledge in the respiratory field will add another layer of expertise for Veritas moving into the future.”

The Company would also like to announce that it has commenced trading on the Frankfurt Stock Exchange under the trading symbol “2VP”.

About VERITAS Pharma Inc.

Veritas Pharma Inc. is an early stage pharmaceutical company developing innovative medicinal cannabis cultivars for specific disease conditions such as chronic pain, emesis (nausea/vomiting), and epilepsy. Using a ‘lean and mean’ approach to product development, the company aims to select candidate cultivars using classical pharmacology techniques and then immediately evaluate them in the clinic to maximize both product value and shareholder return. Veritas’s scientists are an inter-disciplinary team that consists of chemists, pharmacologists, anesthetists, and clinical pharmacologists. Their focus is to use their knowledge to streamline the development of cannabis based treatments to capture considerable market share. Also through its wholly owned subsidiary, Sechelt Organic Marijuana Corp., has applied to Health Canada for a medical marijuana production and distribution license under the Marihuana for Medical Purposes Regulations (the “MMPR“).

On behalf of the Board of Directors Veritas Pharma Inc.
“Dr. Lui Franciosi”
Dr. Lui Franciosi
Chief Executive Officer

Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com.

Investor and Public Relations Contact

Veritas Pharma Inc.
Dr. Lui Franciosi
Chief Executive Officer
Telephone: +1.778.968.6260
Email: [email protected]

The CSE has not reviewed, nor approved or disapproved the content of this press release.

The Veritas Newsletter

Enter your email to receive news alerts and updates from Veritas Pharma.

You have Successfully Subscribed!